Mogamulizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HAS (France), among others, recommended or restricted mogamulizumab, while AOTMIT (Poland), CIPM (Spain) and NYE METODER (Norway) did not recommend it.
Assessment has run over 6.2 years, from 14 May 2019 at AWMSG (Wales) to 24 Aug 2025 at NYE METODER (Norway).
PBAC (Australia) changed its position: not recommended in 2020, recommended by 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 5 of 15 records date from 2023 or later.
5 distinct indication wordings are recorded for mogamulizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess mogamulizumab, on 14 May 2019; NYE METODER (Norway) did not open a file until 24 Aug 2025 — a wide spread of 6.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 12 decisive outcomes narrowed mogamulizumab to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), G-BA (Germany) and NICE (England) among others.
2 of the 11 agencies here assessed mogamulizumab more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for mogamulizumab.
The full ledger for mogamulizumab reads 4 not recommended, 4 recommended, 4 restricted and 1 advice, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 24 Aug 2025 | Behandling av voksne med mycosis fungoides (MF) eller Sézarys syndrom (SS) som tidligere har fått minst én systemisk beh… | not introduced | source |
| PBAC (Australia) | 2025 | Cutaneous T-cell lymphoma (CTCL) | Recommended | source |
| AOTMIT (Poland) | 26 Jan 2024 | programu lekowego „Leczenie chorych na chłoniaki T-komórkowe (ICD 10 C84) | not recommended | source |
| HIRA (South Korea) | 7 Dec 2023 | 균상식육종 또는 시자리증후군 | reimbursement appropriate | source |
| CIPM (Spain) | 3 Feb 2022 | Indicación terapéutica autorizada: Poteligeo está indicado en indicado para el tratamiento de pacientes adultos con mico… | not financed by the SNS · art. 92 d, e | source |
10 further decisions for mogamulizumab, across 7 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 15 decisions for mogamulizumab from 11 agencies, 2019 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.